LK
Li, Kan
2 yayın · 385 atıf · 2023–2024
Yayın
2
Atıf
385
Yıllar
2
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results
|
2024 | Meeting Abstract | 1 |
|
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
|
2023 | Article | 384 |